Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

被引：40

作者：

Aletaha, Daniel ^{[1
]}

Kerschbaumer, Andreas ^{[1
]}

Kastrati, Kastriot ^{[1
]}

Dejaco, Christian ^{[2
,3
]}

Dougados, Maxime ^{[4
]}

McInnes, Iain B. ^{[5
]}

Sattar, Naveed ^{[6
]}

Stamm, Tanja A. ^{[7
]}

Takeuchi, Tsutomu ^{[8
]}

Trauner, Michael ^{[9
]}

van der Heijde, Desiree ^{[10
,11
]}

Voshaar, Marieke ^{[12
]}

Winthrop, Kevin L. ^{[13
]}

Ravelli, Angelo ^{[14
]}

Betteridge, Neil ^{[15
]}

Burmester, Gerd-Ruediger R. ^{[16
]}

Bijlsma, Johannes W. J. ^{[17
]}

Bykerk, Vivian ^{[18
]}

Caporali, Roberto ^{[19
]}

Choy, Ernest H. ^{[20
]}

Codreanu, Catalin ^{[21
]}

Combe, Bernard ^{[22
]}

Crow, Mary K. ^{[23
]}

de Wit, Maarten ^{[24
]}

Emery, Paul ^{[25
,26
]}

Fleischmann, Roy M. ^{[27
]}

Gabay, Cem ^{[28
]}

Hetland, Merete Lund ^{[29
,30
]}

Hyrich, Kimme L. ^{[31
]}

Iagnocco, Annamaria ^{[32
]}

Isaacs, John D. ^{[33
]}

Kremer, Joel M. ^{[34
]}

Mariette, Xavier ^{[35
,36
]}

Merkel, Peter ^{[37
]}

Mysler, Eduardo F. ^{[38
]}

Nash, Peter ^{[39
]}

Nurmohamed, Michael T. ^{[40
]}

Pavelka, Karel ^{[41
]}

Poor, Gyula ^{[42
]}

Rubbert-Roth, Andrea ^{[43
]}

Schulze-Koops, Hendrik ^{[44
]}

Strangfeld, Anja ^{[45
]}

Tanaka, Yoshiya ^{[46
]}

Smolen, Josef S. ^{[1
]}

机构：

[1] Med Univ Vienna, Div Rheumatol, A-1090 Vienna, Austria

[2] Med Univ Graz, Rheumatol, Graz, Austria

[3] Brun Hosp, Rheumatol, Brunico, Italy

[4] Univ Paris 05, Rheumatol, Fac Med Site Cochin, Paris, France

[5] Univ Glasgow, Inst Infect Immunity & Inflammat, Glasgow, Lanark, Scotland

[6] British Heart Fdn Glasgow Cardiovasc Res Cent, Inst Cardiovasc & Med Sci, Glasgow, Scotland

[7] Med Univ Vienna, Sect Outcomes Res, Vienna, Austria

[8] Keio Univ, Dept Internal Med, Div Rheumatol, Grad Sch Med,Sch Med, Shinjuku ku, Tokyo, Japan

[9] Med Univ Vienna, Div Gastroenterol & Hepatol, Vienna, Austria

[10] Leiden Univ, Rheumatol, Med Ctr, Leiden, Netherlands

[11] Diakonhjemmet Hosp, Rheumatol, Oslo, Norway

[12] Univ Twente, Netherlands & Stichting Tools Patient Empowerment, Dept Psychol Hlth & Technol, Enschede, Netherlands

[13] Oregon Hlth & Sci Univ, Div Infect Dis, Sch Med & Publ Hlth, Portland, OR USA

[14] Ist Giannina Gaslini, U O Pediatria Reumatol 2, Genoa, Italy

[15] Neil Betteridge Assoc Ltd, London, England

[16] Charite, Rheumatol & Clin Immunol, Berlin, Germany

[17] Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands

[18] Univ Toronto, Rheumatol, Toronto, ON, Canada

[19] Univ Milan, Dept Clin Sci & Community Hlth, ASS G Pini, Milan, Italy

[20] Cardiff Univ, Rheumatol Sect, Sch Med, Div Infect & Immun,CREATE Ctr, Cardiff, Wales

[21] Carol Davila Univ Med & Pharm, Rheumatol, Bucharest, Romania

[22] CHU Lapeyronie, Immunorhumatol, Montpellier, France

[23] Hosp Special Surg, Mary Kirkland Ctr Lupus Res, New York, NY USA

[24] Univ Amsterdam, Med Humanities, Med Ctr, Duivendrecht, Netherlands

[25] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[26] Leeds Teaching Hosp NHS Trust, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England

[27] Univ Texas Southwestern Med Ctr Dallas, Med, Dallas, TX USA

[28] Univ Hosp Geneva, Div Rheumatol, Geneva, Switzerland

[29] Copenhagen Univ Hosp, Dept Clin Med, Copenhagen, Denmark

[30] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

[31] Univ Manchester, Ctr Epidemiol Versus Arthrit, Manchester Acad Hlth Sci Ctr, Manchester, England

[32] Univ Torino, Sci Clin Biol, Turin, Italy

[33] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[34] Albany Med Coll, Med Rheumatol, Albany, NY USA

[35] Assistance Publ Hop Paris, Rheumatol, Paris, France

[36] Univ Paris, Ctr Immunol Viral Infect & Autoimmune Dis, Gif Sur Yvette, France

[37] Univ Penn, Rheumatol, Philadelphia, PA USA

[38] Organizac Med Invest SA, Buenos Aires, DF, Argentina

[39] Griffith Univ, Sch Med, Gold Coast, Qld, Australia

[40] Amsterdam UMC Locat VUmc, Rheumatol, Amsterdam, Netherlands

[41] Charles Univ Prague, Rheumatol Dept, Prague, Czech Republic

[42] Semmelweis Univ, Natl Inst Rheumatol & Physiol, Budapest, Hungary

[43] Kantonssp Sankt Gallen, Div Rheumatol, St Gallen, Switzerland

[44] Ludwig Maximilians Univ Munchen, Divis Rheumatol & Clin Immunol Internal Med 4, Munich, Germany

[45] Forschungsbereich Epidemiol Deutsch Rheuma Forsch, Berlin, Germany

[46] Univ Occupat & Environm Hlth, Dept Internal Med 1, Kitakyushu, Japan

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 06期

关键词：

rheumatoid arthritis; biological therapy; autoimmune diseases; JUVENILE IDIOPATHIC ARTHRITIS; GIANT-CELL ARTERITIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACTIVE RHEUMATOID-ARTHRITIS; NECROSIS-FACTOR INHIBITORS; OPTICA SPECTRUM DISORDER; DOUBLE-BLIND; OPEN-LABEL; DISEASE-ACTIVITY; SUBCUTANEOUS TOCILIZUMAB;

D O I：

10.1136/ard-2022-222784

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6R alpha antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. Methods A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. Results The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. Conclusions The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.

引用

页码：773 / 787

页数：15

共 174 条

[1] Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review [J].